BI-1136

BI-1136 is an orally bioavailable, small-molecule, selective degrader of B-cell lymphoma 6 protein (BCL6) developed by Boehringer Ingelheim as a targeted protein degradation tool compound. It binds to the BTB/POZ domain of BCL6, disrupts interactions with corepressors, and induces proteasomal degradation of BCL6, leading to potent suppression of BCL6-dependent transcriptional programs in mouse and human diffuse large B-cell lymphoma (DLBCL) cell lines and other BCL6-expressing cells.[1][2][3][5][11] BI-1136 shows high selectivity in receptor and kinase panels, favorable pharmacokinetic properties in rodents, and in vivo activity and tolerability, and is being shared via the opnMe platform for preclinical research in oncology, immunology, and metabolic diseases, including diabetes mellitus and non-alcoholic fatty liver disease where BCL6 inhibition is being explored as a therapeutic strategy.[1][2][3][5][11]

Other names

oral BCL6 degrader BI-1136